Free Trial
NASDAQ:SILO

Silo Pharma 3/28/2025 Earnings Report

Silo Pharma logo
$0.82 +0.03 (+4.08%)
Closing price 04:00 PM Eastern
Extended Trading
$0.80 -0.02 (-2.38%)
As of 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Silo Pharma EPS Results

Actual EPS
-$0.41
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Silo Pharma Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Silo Pharma Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Silo Pharma's next earnings date is estimated for Tuesday, November 11, 2025, based on past reporting schedules.

Conference Call Resources

Silo Pharma Earnings Headlines

Stunning new initiative unfolding in the White House?
what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.tc pixel
See More Silo Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Silo Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Silo Pharma and other key companies, straight to your email.

About Silo Pharma

Silo Pharma (NASDAQ:SILO) (NASDAQ:SILO) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel psychedelic and related synthetic therapies. Headquartered in New York City, the company applies proprietary chemistry and targeted drug delivery approaches to advance candidates that address critical unmet needs across oncology, neurology and mental health.

The company’s preclinical and early-stage clinical pipeline comprises several programs that explore serotonin receptor modulators, synthetic analogs of classic psychoactive compounds and neuroprotective agents. Key initiatives include research into treatments for chemotherapy-induced neurotoxicity, glioblastoma, neurodegenerative disorders and mood conditions such as depression and post-traumatic stress disorder. Silo Pharma leverages strategic collaborations and material licensing agreements with leading academic institutions to accelerate its research efforts.

Originally founded as Elicio Therapeutics in 2019, the firm rebranded to Silo Pharma in 2021 to underscore its specialized focus on psychedelics and novel CNS therapies. In addition to its U.S. operations, the company engages in collaborative research activities with partners in Canada and Europe. Silo Pharma’s leadership team brings together expertise in pharmaceutical R&D, regulatory strategy and business development to position the company for growth in the emerging psychedelics sector.

View Silo Pharma Profile

More Earnings Resources from MarketBeat